The Remote Scalpel: Precision IO's Bid to Decentralize Cancer Surgery

MIAMI, FL – July 20, 2026 – This week, the world of robotic surgery will turn its attention to Hollywood, Florida, where a newly formed medtech heavyweight, Precision IO Group, is set to detail its ambitious strategy for reshaping cancer treatment. At the Society of Robotic Surgery (SRS) Annual Meeting, the company will showcase its AI-powered Epione® robotic platform and unveil a forward-looking program for remote interventions, signaling a future where a patient’s zip code no longer dictates their access to world-class cancer care.

The presentations, led by top interventional radiologists and the company’s CEO, Kurt Azarbarzin, aim to spotlight how the fusion of robotics, artificial intelligence, and telerobotics can deliver unprecedented precision in tumor ablation while systematically dismantling geographic barriers to specialized medical expertise.

A New Force in Interventional Oncology

Precision IO Group is a new but formidable name, forged in a strategic move earlier this year. The company was established in February 2026 following the acquisition of NeuWave Medical from Johnson & Johnson MedTech by Quantum Surgical. Both firms now operate as subsidiaries under the Precision IO Group parent company, creating a powerhouse that combines Quantum Surgical's European leadership in robotics and AI with NeuWave's dominant U.S. market position in microwave ablation technology. NeuWave’s systems are already a staple, used in over 70% of top American cancer centers for treating soft tissue tumors.

This consolidation was heavily backed by lead investor Ally Bridge Group, a global healthcare investment firm that has been a long-term supporter of Quantum Surgical, having led a €40 million funding round in 2021. With over 275 employees worldwide and veteran medtech executive Kurt Azarbarzin at the helm, Precision IO Group is positioned not just to compete, but to define the next era of minimally invasive oncology. The company's stated mission is to make precision cancer care universally available, a goal it intends to achieve by empowering physicians with more consistent and evidence-backed solutions for treating complex tumors.

"Today, subspecialty expertise in tumor ablation is concentrated in a small number of centers globally," said Kurt Azarbarzin, CEO of Precision IO Group, in a recent statement. "Through our remote intervention program and AI-enabled planning on Epione, our goal is to continue to extend access to cancer care for patients everywhere."

Epione: The AI-Guided Robotic Hand

At the heart of Precision IO's strategy is the Epione® platform, a sophisticated robotic system designed to elevate the art of percutaneous tumor ablation—a minimally invasive procedure where a needle-like probe is guided through the skin to destroy a tumor. The current challenge with these procedures is the high degree of difficulty in navigating to small or awkwardly located tumors, a limitation Epione aims to solve.

The platform integrates CT-guided planning, AI-assisted targeting, and robotic guidance into a seamless workflow. This allows a physician to plan the optimal path to a tumor on a 3D image and then rely on the robotic arm to guide the instrument to the precise target through a single skin puncture with sub-millimeter accuracy. Since its introduction, over 1,700 patients have been treated with Epione across more than 20 cancer centers in Europe and the United States.

While the technology has gained significant traction, its regulatory pathway reflects a careful, indication-by-indication approach. Epione holds a CE Mark in Europe for use in the abdomen, chest, and musculoskeletal (MSK) structures, including bone. In the United States, it is FDA cleared for abdominal ablations. However, its use for bone tumors in the U.S. remains investigational. To that end, the company launched the "EPIOS" clinical study in May 2026 to gather the necessary data to secure FDA clearance for these MSK applications, treating its first U.S. patient in the trial on April 28.

The Telerobotic Frontier: Bridging the Care Gap

The most transformative aspect of Precision IO's vision is its remote intervention program. Currently in development, this initiative aims to leverage the Epione platform to create a telerobotics network that connects specialists with patients and physicians anywhere in the world. The initial phase focuses on enabling remote trajectory planning and post-procedure assessment, allowing a leading expert in New York or Paris to collaborate in real-time on a procedure happening hundreds or thousands of miles away.

This model directly addresses one of modern healthcare’s most persistent challenges: geographic disparity. For complex cancers, outcomes are often tied to the experience of the treating physician, yet that expertise is heavily concentrated in major urban academic centers. The remote program seeks to decentralize this knowledge, effectively exporting the skills of top interventional radiologists without requiring them to travel.

Dr. Govindarajan Narayanan, the first physician to use Epione in the United States three years ago, will be speaking on this very topic at the SRS meeting. "Robotic assistance is now a routine part of how I plan and perform percutaneous ablations. The next barrier is geography," he stated. "Remote trajectory planning and results assessment are a practical first step toward putting this level of care within reach of patients far from specialized centers."

While the promise is immense, the path to widespread remote surgery is paved with technical and regulatory challenges, including ensuring network stability, cybersecurity, and navigating cross-state and international medical licensing laws. However, Precision IO's phased approach, starting with planning and assessment, offers a pragmatic route to building the infrastructure and confidence needed for a fully remote-enabled future.

Strategic Showcase at the SRS Annual Meeting

Precision IO Group's significant presence at the SRS meeting is a clear strategic play. The conference is a premier gathering of the pioneers and practitioners driving the field of robotic surgery, making it the ideal venue to validate their technology and vision. The company's booth will feature live demonstrations of Epione, giving surgeons hands-on exposure to the system.

Beyond the technology showcase, the speaking sessions are poised to make a significant impact. CEO Kurt Azarbarzin's participation in the "Innovative Robotic Technologies" investor session will frame the company's financial and strategic value proposition. Meanwhile, the clinical presentations by Dr. Sean Tutton on image-guided ablation for MSK tumors and Dr. Narayanan on the telesurgical platform will provide peer-to-peer evidence of the system's real-world utility and future potential. By combining investor-facing strategy with clinician-led validation, Precision IO is making a comprehensive case for its central role in the future of interventional oncology.